Supriya Lifescience LimitedSUPRIYACorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Dec 2025 1 quarters of data

₹886.00

MCap ₹7,131 Cr

Supriya Lifescience Limited — Stock analysis & AI research Supriya Lifescience Limited — Seasonality — best & worst months Supriya Lifescience Limited — Technical indicators & charts Supriya Lifescience Limited — Technical setup — score, trend, support & resistance Supriya Lifescience Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 High Profit Growth Stocks 📋 Low Debt Stocks 📋 High Promoter Holding Stocks 📈 Volume Dry-Up Stocks 📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹206 Cr

Sales · Dec 2025

₹72 Cr

Operating Profit · Dec 2025

34.9%

OPM % · Dec 2025

₹50 Cr

Net Profit · Dec 2025

₹6.17

EPS · Dec 2025

📝 Supriya Lifescience Limited — results explained

Quarter ended December 2025 (Q3 FY26)

Supriya Lifescience Limited reported revenue of ₹206 crore for the quarter ended December 2025 (Q3 FY26).

Net profit stood at ₹50 crore. Earnings per share (EPS) came in at ₹6.17.

Operating profit stood at ₹72 crore — an operating margin (OPM) of 34.9%.

Valuation snapshot

At the current price of ₹886.00, SUPRIYA has a market capitalisation of ₹7,131 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 5th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 68.30%, foreign institutional investors (FIIs) 6.44%, domestic institutional investors (DIIs) 5.47%, public shareholders 19.79% of Supriya Lifescience Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹7,131 Cr

Current Price ?

₹886.0

P/E ?

N/A

Industry P/E ?

37.20

P/B ?

5.95

P/S ?

N/A

P/FCF ?

3,565.39

Enterprise Value ?

₹7,136 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

25.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹206 Cr

PAT — latest qtr ?

₹50 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹5 Cr

Debt to Equity ?

0.00

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

68.30%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

6.9%

Return 6 months ?

38.8%

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Dec bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2025	YoY %	QoQ %
Sales	206	—	—
Operating Profit	72	—	—
Other Income	3	—	—
Interest	0	—	—
Depreciation	7	—	—
Profit Before Tax	67	—	—
Net Profit	50	—	—
EPS	6.17	—	—
OPM %	34.9%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	16	16	16	16	+0.0%
Reserves	683	799	981	1,182	+20.5%
Borrowings	22	5	5	5	+0.0%
Other Liabilities	98	101	110	154	+40.0%
Total Liabilities	820	921	1,112	1,357	+22.0%
Fixed Assets	262	310	453	689	+52.1%
CWIP	68	149	148	36	-75.7%
Investments	25	64	63	99	+57.1%
Other Assets	466	399	448	534	+19.2%
Total Assets	820	921	1,112	1,357	+22.0%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	% Chg
Cash from Operating Activity	49	64	113	165	+46.0%
Cash from Investing Activity	-60	-124	-174	-152	+12.6%
Cash from Financing Activity	150	-10	-22	-8	+63.6%
Net Cash Flow	139	-70	-83	4	+104.8%
Free Cash Flow	-11	-44	-32	2	+106.2%
CFO/OP	51%	73%	86%	86%	+0.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	67	71	70	97	+38.6%
Inventory Days	234	140	205	229	+11.7%
Days Payable	130	98	129	159	+23.3%
Cash Conversion Cycle	171	114	146	167	+14.4%
Working Capital Days	168	157	144	147	+2.1%
ROCE %	19%	22%	27%	25%	-7.4%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	+0.0%
FIIs	6.78%	5.46%	5.19%	5.16%	6.19%	6.44%	+4.0%
DIIs	4.86%	5.22%	5.00%	5.70%	5.30%	5.47%	+3.2%
Public	20.08%	21.02%	21.49%	20.83%	20.21%	19.79%	-2.1%
No. of Shareholders	91,928	87,912	85,099	81,161	82,082	78,561	-4.3%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	KOPRAN Kopran	₹281.55	1,361	54.5	700	25	8.7%	3.6%	-96.0%	-97.6%	13.9%	-10.0%

❓ Frequently asked questions

What was Supriya Lifescience Limited's revenue in Q3 FY26?